Navigation Links
Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
Date:2/13/2008

Competitive Advantages in Efficacy Will Drive Prescription Rates, According

to a New Report from Decision Resources

WALTHAM, Mass., Feb. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, following its approval in early 2009, Centocor/Janssen-Cilag's ustekinumab will become the clinical gold standard for psoriasis by 2011. Ustekinumab will achieve gold standard status because of its competitive advantages in long-term efficacy over Centocor/Schering- Plough/Mitsubishi Tanabe's Remicade and due to its superior effect on plaque clearance when compared to Amgen/Wyeth/Takeda's Enbrel.

According to the new report entitled Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011, ustekinumab has competitive advantages in efficacy, the area of the highest importance to surveyed physicians, and a superior safety and delivery profile when compared to Remicade. Surveyed dermatologists report that a drug's effect on plaque clearance is the attribute that most influences their prescribing decisions in psoriasis and clinical data shows that ustekinumab has advantages over sales-leading Enbrel on this attribute.

"Clinical data and thought leader opinion indicate that ustekinumab and Abbott/Eisai's Humira outperform Enbrel on efficacy and delivery measures," said Irene Koulinska, analyst at Decision Resources. "But the major improvement in efficacy offered by ustekinumab will earn it future gold- standard status."

About the Report

Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011 is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market sh
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
2. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
3. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
4. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
5. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
6. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
7. Solazyme Selected for National Institute of Standards and Technology Award
8. MyClyns(TM), a New Standard of Personal Protection, is Announced at the EMS and Firehouse Central EXPO
9. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
10. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... ROCKVILLE, Md. , April 16, 2015 /PRNewswire/ ... "RegeneRx") today announced its U.S. joint venture with ... conduct a phase 3 clinical trial for the ... dose-response, confirmatory trial for dry eye syndrome (DES) ... ReGenTree,s preservative-free eye drops, RGN-259/GBT201, this year.  Each ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... April 16, 2015 Avelas Biosciences, an ... cancer surgeries, announced today that it has initiated a ... AVB-620, in women with primary, non-recurrent breast cancer undergoing ... welcomed the addition of Steven Chen , M.D., ... open label, dose escalation study will enroll up to ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... 2011   Elsevier, the leading ... will present awards to outstanding members of the wilderness medicine ... Wilderness Medicine Scientific Conference & Annual Meeting , taking place ... rd . The aim of the Wilderness Medicine ...
... Switzerland and RALEIGH, North Carolina, July 26, 2011 ... a therapeutically focused contract research organisation (CRO) with ... Debiopharm Group™ ("Debiopharm"), a Swiss-based global biopharmaceutical group ... diagnostics, today announced a strategic partnership. Under the ...
... 25, 2011 Rising star Divine Skin Inc. (DSKX), which ... Robin Powell, a long-time leader in the cosmetics industry, to ... of retirement by Divine Skin because I believe their innovative ... give proven results with a ,wow, factor." ...
Cached Biology Technology:Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 2Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 3INC Research and Debiopharm Group(TM) Announce Strategic Partnership 2INC Research and Debiopharm Group(TM) Announce Strategic Partnership 3Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... New research from the University of Michigan Comprehensive ... protein that fuels an inflammatory pathway does not turn ... cancer stem cells. This provides a potential target for ... of the disease. The researchers identified a protein, ...
... glioblastoma cancers so difficult to treat is that malignant cells ... fibers and blood vessels to invade new locations. Now, researchers ... the cancer by using a film of nanofibers thinner than ... of invading new areas, the migrating cells latch onto the ...
... life on earth, is also its least explored environment. ... the ocean,s deep regions, exploiting the deep,s resources and ... for the planet at risk. Lisa Levin, a ... San Diego, believes the vital functions provided by the ...
Cached Biology News:New finding points to potential options for attacking stem cells in triple-negative breast cancer 2Researchers hijack cancer migration mechanism to 'move' brain tumors 2Researchers hijack cancer migration mechanism to 'move' brain tumors 3Researchers hijack cancer migration mechanism to 'move' brain tumors 4Scientists call for new stewardship of the deep ocean: Earth's last frontier 2Scientists call for new stewardship of the deep ocean: Earth's last frontier 3
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
Contains L-glutamine...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: